Finally, preliminary data from CML patients suggest that ZNF224 could be a novel biomarker at diagnosis to predict the imatinib sensitivity in patients with chronic myelogenous leukemia, although analysis of ZNF224 expression levels in a larger cohort of patients is required in order to assess its potential use in clinical practice. Here, ZNF224 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.